Group 1 - The Hong Kong innovative drug sector experienced a strong rally, with the Hong Kong medical ETF (159718.SZ) rising by 1.04% and net subscriptions of 3 million units during the day [1] - Notable stocks such as Jinxin Fertility (01951) increased by 5.51%, Weimaitong (02192) by 5.13%, and Shenwei Pharmaceutical (02877) by 4.45% [1] - The negotiation for the 2025 National Basic Medical Insurance Drug List and the price negotiation for commercial insurance innovative drug list was completed, with 120 domestic and foreign companies participating [1] Group 2 - The innovative drug sector sentiment has recently declined, but with ongoing business development (BD) activities, the sector's sustainability is expected to continue [2] - The current investment and financing data, orders, and performance metrics show a positive trend in the innovative drug industry chain [2] - The Hong Kong medical ETF includes a balanced composition of innovative drugs, CXO, internet healthcare, and innovative devices, making it a convenient tool for investors [2]
创新药利好不断，港股医药ETF(159718.SZ)午后强势拉升
Sou Hu Cai Jing·2025-11-10 06:05